Index

abdominal aortic aneurysm, 35
absorbent and incontinence products
  fecal incontinence, 370
  urinary incontinence, 359
  absorption, pharmaceutical, 44
Abuse Intervention Model, 669
acamprosate, 265
Accurate Hierarchical Conditions Category (HCC), 739
acetylcholinesterase inhibitors, 121
Achilles tendinitis, 564
acrochordons, 459
actina purpura, 460
actinic keratosis, 461
action tremors, 218
activity, defined, 580
acupuncture, 690
acute ischemic stroke, 212–213
acute kidney injury (AKI), 325
acute myelogenous leukemia (AML), 501–502
acute otitis externa (AOE), 536–537
acute spontaneous intracerebral hemorrhage, 210
acute ST-segment elevation myocardial infarction (STEMI), 145
adrenal insufficiency (AI), 391–392
adrenal nodules, 390
advance directives
  defined, 762
  documentation process, 764
  formulation process, 763
  legalities of, 762
  limitations of, 762
  person-centered care (chronic kidney disease), 332
  physician role in, 763
types of, 762–763
adverse drug reactions (ADRs) in the elderly
chronic obstructive pulmonary disease (COPD), 274
cognitive impairment, 48–49
falls, 47–48
in intensive care, 280
overview, 47
Age Discrimination in Employment Act of 1967, 700
age-related macular degeneration, 531–532
aging interventions
  biology of aging advances, 14–15
  challenges, 17–18
  clinical trial design, 16–17
  prescriptive models, 15–16
  summary of, 12
  translational aging research, 12–14
albuminuria category (kidney disease), 325
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), 259
alcohol abuse
  definitions, 257
  and HIV, 316–317
  pharmacology, 264–265
  prevalence of, 257
  screening for, 39
  sensory disorders and, 194
  withdrawal treatment, 263–265
Alcohol Use Disorders Identification Test (AUDIT), 39, 259–260
Alexander technique, 687
Alternative Payment Models (APMs), 739
Alzheimer’s disease (AD)
  defined, 116
  diagnosis, 116–117
  diagnostic testing, 116
  disease-oriented therapies for, 119
  home and community-based care, 623–624
  psychotic symptoms in, 252
  REACH intervention trial (Resources for Enhancing Alzheimer’s Caregiver Health), 730–731
  risk factors, 116
  time frame to death, 117
Alzheimer’s disease (AD), neuropsychiatric symptoms
  Describe, Investigate, Create, and Evaluate (DICE) approach, 121
  nonpharmacological, 121–122
Alzheimer’s disease (AD), symptomatic therapies
  acetylcholinesterase inhibitors, 121
memantine, 121
amantadine, 223
amputation, lower extremity, 589
amyloid cardiomyopathy, 153–155
amyotrophic lateral sclerosis (ALS), 191
anemia in the elderly
  autoimmune hemolytic anemia (AIHA), 497–498
  classification, 493
  clinical consequences, 493
  clinical presentation, 493–494
defined, 493
etiology of, 493
anemia in the elderly, macrocytic
  myelodysplastic syndrome, 497
anemia in the elderly, normocytic
  anemia of chronic kidney disease (CKD), 496
  anemia of inflammation (AI), 495–496
  anemia of chronic kidney disease (CKD), 496
anemia in the elderly, microcytic
  vitamin B12 deficiency, 497
  anemia in the elderly, microcytic iron deficiency, 494–495
  thalassemia, 495
anemia in the elderly, normocytic
  anemia of chronic kidney disease (CKD), 496
anorexia, 56
anosmia, 541
antibiotic resistance in the elderly
growing threat of, 303
Clostridium difficile, 304
growing threat of, 303
methicillin-resistant S. aureus (MSRA), 303–304
anticoagulation for stroke prevention
direct thrombin inhibitors and oral factor Xa agents, 211
in hemorrhagic stroke, 212
indications for, 212
mechanical closure, 211
timing of, 211
warfarin, 211
antidepressants and crash risk, 677
dosage recommendations, 253
effectiveness of, 248–249
antiepileptic drugs and crash risk, 677
antihistamines and crash risk, 677
exercise guidelines for, 72
antiplatelet therapy for stroke prevention
aspirin, 210
clopidogrel, 211
dual antiplatelet therapy (DAPT), 211
antipsychotics, 136
antithrombotic therapy, 185
anxiety disorders in the elderly, 247
aortic insufficiency, 157
aortic stenosis (AS)
clinical presentation, 156
diagnosis, 156
epidemiology, 156
management, 156–157
apixaban, 211
aromatherapy, 689–690
arthritis, exercise guidelines for, 67
arthroplasty and physical activity, 70
aspirin colorectal cancer (CRC), 514
diabetes mellitus, 403
for stroke prevention, 210
Assessing Care of Vulnerable Elders
(ALCOVE-2), 27
assessment, geriatric cancer, 506–507
comprehensive geriatric assessment (CGA), 21–29
essential principles of elder care, 6–7
pressure injuries, 485
assessment, geriatric preoperative cardiopulmonary risk, 571
clinical evaluation, 571
cognitive evaluation, 569–570
FIT CHAMP mnemonic, 572
functional evaluation, 570–571
goals of care, 570
history and physical exam, 569
polypharmacy, 571–572
rehabilitation, 572
risk assessment and referrals, 572
asthma-COPD overlap syndrome (ACOS), 271
asymptomatic bacteriuria epidemiology, 298–299
management, 299
atelectasis, 573
atherosclerotic cardiovascular disease (ASCVD), 410–411
athlete’s foot, 560
topic dermatitis, 465–466
atrial fibrillation (AF) clinical presentation, 160
incidence of, 159–160
postoperative, 160
and stroke risk, 211
atrial fibrillation (AF) management ablation, 161
complications, 162
DOACs, 161
focus of, 160
stroke and, 161
thromboembolism and, 160–161
atrial fibrillation, 290
atrial fibrillation guidelines, 346, 373
auditory loss otolaryngology, 538
autism spectrum disorder (ASD) caregivers for, 613
common comorbidities, 613
definition, 612
etiology of, 612
life expectancy, 613
overlap with SPMI and ID, 614
prevalence of, 612–613
treatment best practices, 613
autoimmune blistering disorders (AIBD), 468–469
autoimmune hemolytic anemia (AIHA), 497–498
autonomy. See patient autonomy in elderly health
bacterial pneumonia diagnosis, 299
etiology of, 300
management, 299–300
risk factors for, 299
balance examination background of, 94
findings, 94
balance in otolaryngology age-related changes, 539
common pathologies, 539
Barrett’s esophagus (BE), 287–288
basal cell carcinoma, 460–462, 525
primary hyperparathyroidism (PHPT), 422
remitting seronegative symmetric synovitis with pitting edema (RS3PE), 431
renal osteodystrophy, 423
rheumatoid arthritis (RA), 427–428
Secondary hyperparathyroidism, 422
Sjögren’s syndrome, 431
summary of, 422
brachytherapy, 513
bradycardia, 159
breast cancer characteristics, 508
clinical presentation, 509
epidemiology, 508
prevention of, 509
prognosis, 509
withdrawal treatment, 265
benzotropine, 223
beta-blockers for heart failure (HF), 151
for hypertension, 178
for myocardial infarction, 144
binge drinking, 257
bioavailability, pharmaceutical, 44–45
biofeedback complementary and alternative medicine (CAM), 686
biology of aging advances caloric restriction, 14
Interventions Testing Program (ITP), 15
metformin, 15
mutations for, 14
SASP inhibitors, 14–15
biopsychosocial model of frailty, 82
bipolar disorder, 249
bisphosphonate use and musculoskeletal injuries, 443
bladder cancer clinical presentation, 340
complications, 340
management, 340
bladder outlet obstruction, 352
bleeding, gynecological, 374
bilepharitis, 526
body mass index (BMI), 58
bone conditions of the elderly. See also osteoporosis
calcium pyrophosphate deposition disease (CPPD), 429
giant cell arteritis (GCA), 430–431
gout, 428–429
and HIV, 315
inclusion body myositis (IBM), 431
Paget’s disease, 422–423
polymyalgia rheumatica (PMR), 430
primary hyperparathyroidism (PHPT), 422
remitting seronegative symmetric synovitis with pitting edema (RS3PE), 431
renostentodystrophy, 423
rheumatoid arthritis (RA), 427–428
secondary hyperparathyroidism, 422
Sjögren’s syndrome, 431
summary of, 422
brachytherapy, 513
bradycardia, 159
breast cancer characteristics, 508
clinical presentation, 509
epidemiology, 508
prevention of, 509
prognosis, 509
benzotropine, 223
beta-blockers for heart failure (HF), 151
for hypertension, 178
for myocardial infarction, 144
binge drinking, 257
bioavailability, pharmaceutical, 44–45
biofeedback complementary and alternative medicine (CAM), 686
biology of aging advances caloric restriction, 14
Interventions Testing Program (ITP), 15
metformin, 15
mutations for, 14
SASP inhibitors, 14–15
biopsychosocial model of frailty, 82
bipolar disorder, 249
bisphosphonate use and musculoskeletal injuries, 443
bladder cancer clinical presentation, 340
complications, 340
management, 340
bladder outlet obstruction, 352
bleeding, gynecological, 374
bilepharitis, 526
body mass index (BMI), 58
bone conditions of the elderly. See also osteoporosis
calcium pyrophosphate deposition disease (CPPD), 429
giant cell arteritis (GCA), 430–431
gout, 428–429
and HIV, 315
inclusion body myositis (IBM), 431
Paget’s disease, 422–423
polymyalgia rheumatica (PMR), 430
primary hyperparathyroidism (PHPT), 422
remitting seronegative symmetric synovitis with pitting edema (RS3PE), 431
renostentodystrophy, 423
rheumatoid arthritis (RA), 427–428
secondary hyperparathyroidism, 422
Sjögren’s syndrome, 431
summary of, 422
brachytherapy, 513
bradycardia, 159
breast cancer characteristics, 508
clinical presentation, 509
epidemiology, 508
prevention of, 509
prognosis, 509
Index

goals of, 327
person-centered care, 329–332
preparing for kidney failure, 328
slowing progression, 327
chronic lymphocytic leukemia (CLL), 501
chronic myeloid leukemia (CML), 501
chronic obstructive pulmonary disease (COPD) defined, 271
diagnosis, 271
epidemiology, 270–271
Creutzfeldt-Jakob disease (CJD), 118
crowned dens syndrome (CDS), 429
crutches, 584
cultural competence in health care
defined, 708
LEARN model of cross-cultural
communication, 712–713
National Standards for Culturally and
Linguistically Appropriate Services
(CLAS), 709
provider guidelines, 710–712
questions to ask patients, 712
cultural diversity of older adults. See
ethnogeriatric care
culture, 703
current procedural terminology (CPT)
code, 759
Cushing’s syndrome, 391
dabigatran, 211
DASH diet, 687–688
deep brain stimulation (DBS)
for essential tremors, 219
for Parkinson’s disease, 226–228
defecography, 367
deficit model of frailty, 82
delirium in the elderly
defined, 129
and dementia, 118
etiology of, 130–131
incidence of, 129
overview of, 129
pathophysiology of, 130
prediction of, 130–131
prevention of, 119, 131
delirium in the elderly, evaluation
diagnosis, 131–132
diagnostic studies for, 134
maneuvers for, 133
delirium in the elderly, management
delirium room (DR), 134–135
hyperactive patient, 135
hypoaactive patient, 135
in intensive care, 279
multiple interventions for, 132
patient interaction recommendations, 135
pharmacological, 135–136
postcardural, 573
predisposing and precipitating factors
for, 135
delirium room (DR), 134–135
delusional disorder, 251
dementia in the elderly
cultural component of, 707–708
defined, 112–113
elder abuse and, 668
epidemiology, 112
ethics of care, 766–767

individuals with intellectual
disabilities, 610
key points, 125
risk factors, 112
sleep disorders and, 241–242
dementia in the elderly, diagnosis
cognitive assessment, 114–115
diagnostic testing, 115
evaluation approach, 112–113
genetic testing for, 116
history taking, 113–114
medication review, 114–115
neuroimaging, 115–116
physical exam, 115
psychotic symptoms in, 252
dementia in the elderly, subtypes
Alzheimer’s disease (AD), 116–117
dementia with Lewy bodies (DLB),
117–118
depression and delirium, 118
frontotemporal dementia (FTD), 117
prion disease, 118
rapidly progressive, 118
vascular dementia, 117
dementia in the elderly, supportive care
advance directives, 121–122
caregiving for, 124–125, 729–730
driving safety, 122–124
placement out of home, 124
safety strategies, 122–124
summary of, 123
dementia with Lewy bodies (DLB)
overview of, 117–118
and Parkinson’s disease, 222
demographics
of aging, 1
caregivers for elderly, 4
cultural diversity of older adults, 4
eye working past age 65, 9
fall risk factors, 91
functional deficits in the elderly, 23
oral health in the elderly, 24
physical activity in elderly adults, 64
retirement, 699–700, 702
dental caries, 548–549
epidemiology, 548
etiology of, 548–549
prevalence of, 548
prevention of, 551
sweeten, 551–552
dentistry, 761
depression in the elderly
after stroke, 213
and anxiety, 247–248
chronic, 249
and dementia, 118
electroconvulsive therapy (ECT), 249
epidemiology, 248
etiology of, 248

pharmacology, 248–249
screening, 36
dermatolochalasia, 525
dermatologic conditions in the elderly
hair, nails, and glands, 459
mitigating photaging, 458
skin function changes with aging,
457–458
skin structure changes with aging,
457–458
dermatologic conditions in the elderly,
benign skin lesions
acroderns, 459
actinic purpura, 460
cheri angiomas, 459
epidermal inclusion cysts, 460
sebaceous hyperplasia, 460
seborrheic keratoses, 459
solar lentigines, 459–460
dermatologic conditions in the elderly,
infectious skin diseases
cellulitis, 468–471
erysipelas, 469–470
intertrigo, 472–473
onychomyocysis, 472
scabies, 472
shingles, 471
dermatologic conditions in the elderly,
inflammatory skin diseases
atopic dermatitis, 465–466
autoimmune blistering disorders,
468–469
lower-extremity skin changes, 467–468
pruritus, 466–467
psoriasis, 465
rosacea, 464
seborrhoeic dermatitis, 464–465
dermatologic conditions in the elderly,
malignant skin lesions
actinic keratoses, 461
basal cell carcinoma, 460–462
melanoma, 462–464
squamous cell carcinoma, 461–462
Describe, Investigate, Create, and
Evaluate (DICE) approach, 121
diabetes
cultural component of, 707
and foot ulcers, 564–565
and peripheral artery disease (PAD),
184
diabetes mellitus
vascular risk factors, 402–403
diagnosis, 395–396
epidemiology, 395
exercise guidelines for, 67
nephrothy screening, 404
screening, 35
diabetes mellitus management
cognitive impairment, 404
Index

endometrial cancer
   clinical presentation, 378
   epidemiology, 378
   prognosis, 378
   risk factors for, 378
   treatment, 378
   types of, 378
end-stage renal disease (ESRD), 325
epidemic, 1, 771
epidermal inclusion cysts, 460
epididymitis, 344
epiphora, 525
epistaxis, 541
eplerone, 144
erectile dysfunction (ED), 598–600
erysipelas, 469–470
essential thrombocytosis (ET), 502
essential tremors
   indications for, 218–219
   versus Parkinsonian, 218
   pathophysiology of, 218
   pharmacology, 219
   therapy for, 219
ethics in elderly health
   Choosing Wisely guidelines, 8
   complexity of, 8
   COVID-19, 761
dementia and, 766–767
do no harm principle, 7
   goals of care, 764
   judgment substitution, 767–769
   and medical nihilism, 7–8
   minimal interference when needed, 7
   nutrition and hydration, 769–770
   patient autonomy, 762–764
   personal nature of, 761
   principles of, 761
   ethics in elderly health, actions and intentions
   death from actions, 765–766
   principle of double effect, 764–765
ethnicgeriatric care
caregiving for, 733
cultural competence, 708–713
importance of, 705
practice transformation in, 742–744
team-based care, 743–744
ethnicgeriatric care disparities
disease prevalence, 707–708
quality of care, 705
eustachian tube dysfunction, 538
eutanasia, 765–766
evaluation and assessment in elderly health
   complete understanding of patient, 6
   nonspecific signs and symptoms, 7
   polypharmacy problem, 6–7
   prejudgment avoidance, 6
   wastebasket diagnoses avoidance, 6
   exercise
cardiovascular disease (CVD), 411
   peripheral artery disease (PAD) in elderly adults, 184–185
   external beam radiation therapy (EBRT), 513
   extrapyramidal disorders and gait, 228
   eye movement desensitization and reprocessing therapy (EMDR), 614
falls
   common geriatric health issue, 36
   incidence of, 91
   mortality from, 91
   and surgery potential, 571
falls, clinical assessment
   history, 93–94
   Stopping Elderly Accidents, Deaths and Injuries (STEADI) algorithm, 92–93
falls, physical exam components
   balance, 94
   gait, 94–96
falls, prevention of
   electronic, 96
   exercise guidelines for, 67, 96
   home health care, 96
   hospital based, 96
   interventions, 95–96
   long-term care facility, 96
   whole body vibration, 96
falls, risk factors
   acute trigger, 92
   adverse drug reactions (ADRs) in the elderly, 47–48
   demographics of, 91
   functional deficits, 92
   medical comorbidities, 92
   syncope versus mechanical falls, 92
family and home care
   burden of, 4
   cost of, 4
   demographics of, 4
   options, 3
   role of health-care providers, 3–4
FASl scoring system, 580, 581
fasting, 689
fat pad atrophy, 564
fecal incontinence in the elderly.
   See also urinary incontinence in the elderly
   classification, 365
   epidemiology, 364
   and fecal impaction, 366
   pathophysiology of, 364–365
   types of, 366
   fecal incontinence in the elderly, evaluation
diagnosis, 367
   history taking, 366
   physical exam, 366–367
   specialized tests, 367
   fecal incontinence, 367
flu. See influenza; pneumococcus
foot health in the elderly
   clinical presentation, 558
   epidemiology, 558
   and surgery potential, 571
foot osteoarthritis, 426
foul foot, 563
flopsey eyelid syndrome, 525
flu. See influenza; pneumococcus
foot in the elderly, diseases
   diabetes, 564–565
   gout, 565–566
   foot osteoarthritis, 426
foot dystrophy, 563
foot osteoarthritis, 426
forefoot dysfunction
digit flexus, 562
hallux limitus, 561–562
hallux rigidus, 561–562
hallux valgus, 561
Morton’s neuroma, 562–563
sesamoiditis, 562
stress fractures, 562
Fracture Risk Assessment Tool (FRAX), 35
frailty
   background of, 81
   defined, 81
   screening, 82
   and surgery potential, 570–571
   and translational aging research, 13
   frailty clinical applications
   decision-making, 85
   palliative care, 85–86

© in this web service Cambridge University Press & Assessment
www.cambridge.org
gynecological issues in the elderly, cancer cervical, 379
endometrial, 378
ovarian, 378–379
vaginal, 379–380
vulvar, 379

endometrial, 378
ovarian, 378–379
vaginal, 379–380
vulvar, 379

H1N1 influenza virus, 773–774
hullacinations. See visual hallucinations
hallux limitus, 561–562
hallux rigidus, 561–562
hallux valgus, 561
hammertoe deformity, 562
HAND (HIV-associated neurocognitive disorder), 316
hand osteoarthritis, 425–426
hazardous drinking, 257
head and neck cancer, 543
Head Impulse Nystagmus Test of Skew (HINTS Plus) exam, 106–107
headaches in the elderly
primary headaches, 199
secondary headache syndromes, 199–205
Health Information Technology (HIT), 740
health insurance. See also Medicaid;
Medicare
benefits defined, 752
cost control, 753
goals of, 751
mechanisms of, 751
nursing home, 752
program expenditure statistics, 751
return on investment (ROI), 752–753
risk spread in, 751–752
health literacy
definition, 716
future of, 723
guidelines for, 716
health literacy and technology
alternatives to, 721–722
barriers to, 722
benefits of, 721
chat bots, 722–723
electronic medical records
portal, 722
patient assistance with, 723
health literacy, low
communication strategies for office visit, 719–720
communication strategies for sensory deficits, 720
communication tools for, 720–721
impacts of, 716
prevalence among the elderly, 716
prevalence in general population, 716
print resource optimization, 721
screening tools, 718
Health Plan Employer Data and Information Set (HEDIS), 739
Healthcare Effectiveness Data and Information Set (HEDIS), 66
health-care system
flaws in, 750–751
overview of, 750
health-care system, financials
cost perspectives, 758–759
hospitals, 757
physician, 757–758
principles of, 753–754
healthy sleep, 235
hearing loss
common geriatric health issue, 37
communication tools for, 720
heart disease in elderly adults
aortic insufficiency, 157
aortic stenosis (AS), 156–157
atrial fibrillation (AF), 159–162
bradycardia, 159
cultural component of, 707
effects of aging on cardiovascular and organ systems, 139–141
diagnosis, 157–159
diastolic function, 158
heart failure (HF), 148–156
mitral regurgitation, 158
mitral stenosis, 157–158
myocardial infarction (MI), 139–148
nutrition for, 688
pericardial constriction, 163
pericardial effusion, 163
pericarditis, 163
prevalence of, 139
secondary prevention trials, 410–411
stable ischemic heart disease (SIHD), 146–148
tricuspid regurgitation, 158
ventricular arrhythmias, 162
heart failure (HF)
clinical features, 149
diagnosis, 149–150
epidemiology, 148
evaluation of, 148–149
functional classification, 149
pathophysiology of, 148
prevention of, 149
heart failure (HF) management
ACE inhibitors, 150–151
angiotensin plus neprilysin inhibition, 151
angiotensin receptor blockers (ARBs), 151
anticoagulant drugs, 152
anti-inflammatory drugs, 152
beta-blockers, 151
digoxin, 152
diuretics, 150
heart transplantation, 152–153
implantable devices, 155
intravenous inotropic agents and vasodilators, 152
invabradine, 151
left ventricular assist devices (LVADs), 153
mineralocorticoid antagonists (MRA), 151–152
prognosis, 156
rehospitalization, 155–156
sodium-glucose cotransporter inhibition, 152
heart failure with preserved ejection fraction (HFpEF) and amyloid cardiomyopathy, 153–155
clinical presentation, 153
epidemiology, 153
pharmacology, 154
heel dysfunction
Achilles tendinitis, 564
heel pad syndrome, 564
plantar fasciitis, 563–564
tarsal tunnel syndrome, 564
heel pad syndrome, 564
Helping People Experience Success (HOPES), 612
hematologic malignancies in the elderly
leukemias, 501–502
multiple myeloma, 499–501
hematuroia
classification, 335
epidemiology, 335–336
etiology of, 336
management, 335, 336
hemiparetic gait, 232
hemorrhagic stroke
anticoagulant reversal, 212
arterial (SAH), 212
cerebral amyloid angiopathy (CAA), 210
defined, 210
etiology of, 210
hemorrhagic stroke management
acute ischemic stroke, 210
acute spontaneous intracerebral hemorrhage, 210
hemorrhage, 210
hepatitis A and B immunizations, 38–39
hepatitis B screening, 38
hepatitis C screening, 38–39
herbal medicine, 689
herpes zoster. See shingles
hip fractures
intertrochanteric, 446–448
outcomes, 445–446
presentation, 444–445
principles of, 444
rehabilitation, 588–589
homeopathic medicine, 690
hormone therapy (HT)
for hypopituitarism, 389–390
menopausal, 375
Hospital Elder Life Program, 131
Housing and Urban Development (HUD), 625
human immunodeficiency virus (HIV) in the elderly
epidemiology, 310, 772–773
prevalence of, 310
risk assessment, 310–311
screening difficulties, 310
testing, 311–312
human immunodeficiency virus (HIV) in the elderly, management
bone health, 315
cardiovascular disease (CVD), 314–315
functional decline, 317
goals of, 312–313
HAND (HIV-associated neurocognitive disorder), 316
liver disease, 316–317
multimorbidity, 313–314
peripheral neuropathy, 316
pre-exposure prophylaxis (PrEP), 318–319
preventing advanced aging, 313
psychiatric disorders, 315–316
renal disease, 315
transmission prevention, 317–318
treatment adherence, 317
human papillomavirus (HPV) and otolaryngeal cancer, 550
and sexuality in the elderly, 595–598
hydrocephalus, 231
hypercalcemia of malignancy, 385
hyperlipidemia and peripheral artery disease (PAD), 184
screening, 35
hypertension in elderly adults
clinical evaluation, 175
comorbidities, 175–176
diagnosis, 174
end organ effects, 176
epidemiology, 173
and hemorrhagic stroke, 210
pathophysiology of, 173–174
and peripheral artery disease (PAD), 184
screening, 34–35
treatment benefits, 176–177
hypertension in elderly adults, management
considerations for, 177–178
guidelines for, 177
nonpharmacological, 177
pharmacology, 178
hypothyroidism
epidemiology, 386
examination, 386–387
subclinical, 387
hypnosis, 686
hypnotics, 677
hypoparathyroidism, 385
hypopituitarism
clinical presentation, 388
diagnosis, 388–389
epidemiology, 388
symptoms, 388
treatment, 389–390
hyperthyroidism
epidemiology, 385
screening, 35
subclinical, 386
treatment, 385–386
immune thrombocytopenic purpura, 498–499
immunosenescence, 774
immunotherapy in the elderly, 518
impairment, defined, 580
implantable cardioverter-defibrillators (ICDs), 155
implantable devices for heart failure, 155
inclusion body myositis (IBM), 431
Indian Health Services (IHS), 623
infectious disease in the elderly
aging and, 297
antibiotic resistance, 303–304
asymptomatic bacteriuria, 298–299
bacterial pneumonia, 299–301
diagnosis, 298
environmental vulnerability, 297
epidemiology, 297
influenza, 301
keratitis, 527–528
shingles, 302–303
tuberculosis (TB), 301–302
urinary tract, 298–299
inflammatory bowel disease (IBD), 293
influenza
diagnosis, 301
epidemiology, 301
immunizations, 37–38
management, 301
ingrown toenail, 561
inhalers, 274
inpatient rehabilitation facilities (IRF), 582–583
insomnia in the elderly
3P model, 236
CBT therapy for, 237
clinical presentation, 235
defined, 235
diagnosis, 236
prevalence of, 235
and sleep apnea, 240
insomnia in the elderly, management
exercise guidelines for, 67
pharmacology, 237–239
psychological, 236–238
institutionalization, overutilization of, 3
insulin (diabetes), 402
integrative medicine, defined, 684
intellectual disability (ID) and aging.
See also cognitive impairment
common comorbidities, 605–606
definition, 604
etiology of, 604–605
life expectancy, 605
overlap with SPMI and autism, 614
prevalence of, 605
social determinants of health (SDOH), 506
intellectual disability (ID) and aging,
terprofessional team approach
behavioral health providers (BHPs), 610–611
case managers, 611
occupational therapists, 611
physical therapists, 611
social workers, 611
speech pathologists, 611
intellectual disability (ID) and aging,
treatment
dementia and, 610
diet and exercise, 609–610
medication review, 607–608
pain management, 607–608
patient living environment, 607
patient participation, 606–607
psychological support, 608–609
screening and prevention health, 606
intensive care unit (ICU) and the elderly
advance directives, 280
cognitive impairment, 279
counting assessment method, 279
delirium, 279
mechanical ventilation risk, 280
prevalence of, 279
sepsis, 279–280
intention tremors, 219
interstitial lung disease (ILD)
defined, 275
diagnosis, 275
special considerations, 276
treatment, 275–276
intertrigo, 472–473
Index

Interventions Testing Program (ITP), 15
intracranial stenosis and stroke, 212
intraurethral prostatic stents, 342–343
iron deficiency anemia, 494–495
irritable bowel syndrome (IBS), 294
ivabradine, 151

kidney disease in the elderly
epidemiology, 324–325
key terms in, 318–324
kidney disease in the elderly, clinical evaluation
challenges to, 326–327
history and physical exam, 326
lab and imaging tests, 326
specialist referral, 326
kidney failure, 325
knee osteoarthritis, 426

LEARN model of cross-cultural communication, 712–713
left ventricular assist devices (LVADs) for heart failure (HF), 153
indication for anticoagulation for stroke prevention, 212
leukemias
acute myelogenous leukemia (AML), 501–502
chronic lymphocytic leukemia (CLL), 501
chronic myeloid leukemia (CML), 501
contrasting hemograms, 502
myeloproliferative neoplasms, 502
levodopa, 224
lichen sclerosus, 346, 374
life expectancy factors, 1
lipid disorders management
age and cardiovascular risk, 407–408
age and lipid-lowering therapy, 407–408
age of study population, 407
clinical trials, 408–409
lipid disorders management, cardiovascular disease (CVD)
atherosclerotic cardiovascular disease (ASCVD), 410–411
dietary/behavioral, 411
exercise guidelines for, 411
limitations of, 413
lipid-lowering therapy clinical trials, 408–409
medicine adherence, 414
non-statin therapy, 412–413
primary prevention trials, 409–410
statin therapy, 411–412
statin underutilization, 415
lithium carbonate, 252
living will, 762–763

long-term care for the elderly. See also nursing home
long-term care for the elderly, home and community-based settings
caregiver issues, 629
COVID-19, 628
financial issues, 629
hospital-at-home programs, 628
medical care in, 627–628
long-term care for the elderly, need for, 620
long-term care for the elderly, public residential options
assisted living facilities (ALFs), 626–627
Continuing Care Retirement Communities (CCRCs), 626
Housing and Urban Development (HUD), 625
Naturally Occurring Retirement Communities (NORCs), 625
skilled nursing facilities (SNFs), 758
Village Movement, 625–626

lung cancer
clinical presentation, 516
epidemiology, 516
prevention of, 516
screening, 34, 516
staging, 517
lung cancer management
early stage, 517
locally advanced disease, 517–518
MACRA (Medicare Access and CHIP Reauthorization Act), 739–740
macular degeneration, 531–532
malignant otitis externa (MOE), 537
malnutrition in the elderly. See also nutrition and aging
diagnosis, 295
etiology of, 294–295

guidelines for, 24
obesity, 24
unintended weight loss, 25
malnutrition in the elderly, etiology
cytokines, 55
diminished sense of taste, 55
gastrointestinal, 54–55
neuroendocrine, 54–55
oral integrity, 55
social causes, 56
summary of, 55
malnutrition in the elderly, syndromes
anorexia, 56
cachexia, 56
sarcopenia, 56
sarcopenic obesity, 56–57
Malnutrition Screening Tool (MST), 58
Malnutrition Universal Screening Tool (MUST), 58
manometry, 367
massage and body work, 687
mean corpuscular volume (MCV), 493
Medicaid. See also health insurance
home and community-based care
under, 622
overview of, 756–757
medical assessment (CGA)
cognition, 25
dementia, 114–115
malnutrition, 24–25
mood disorders, 25
polypharmacy, 25
urinary incontinence, 24
Medicare. See also health insurance
history of, 754
home and community-based care
under, 621–622
insurance expenditure percentage, 751
items not covered by, 756
nursing home, 758
payment gap structure of, 754
physician payment metrics, 758
return on investment (ROI), 752–753
Medicare, parts of
overview of, 754
Part A, 755
Part B, 755
Part C, 755–756
Part D, 756
Medicare Advantage (MA) program, 755–756
Medicare Annual Wellness Visit (AWV), 33
meditation, 686
meglitinide drugs (diabetes), 400
melenoma, 462–464
melatonin, 136

© in this web service Cambridge University Press & Assessment
www.cambridge.org
memantine, 121
Ménière’s disease, 539
menopause
hormone therapy (HT), 375
lifestyle changes, 375
pathophysiology of, 375
serotonin reuptake inhibitors (SSRIs), 375
treatment summary, 376
vasomotor symptoms (VMS), 375–376
mental status evaluation
abnormal thoughts, 246–247
cognitive assessment, 247
general appearance, 246
mood, 246
practice transformation, 745–746
speech, 246
suicidal ideation, 246
mesenteric ischemia (MI), 291–292
metabolism and pharmacology, 45
metastatic disease
breast cancer, 511
musculoskeletal injuries and, 442
metformin
and antiaging, 15
for diabetes mellitus, 398–400
exercise guidelines for, 72
methadone, 265–266
methicillin-resistant S. aureus (MRSA) resistance
antibiotic alternatives, 304
diagnosis, 303–304
epidemiology, 303
middle and inner ear otolaryngology
age-related changes, 537
common pathologies, 537–538
midfoot dysfunction
pes planus, 563
posterolateral tibial tendon dysfunction, 563
migraine headaches, 199
migrainous vertigo, 539
mild cognitive impairment (MCI)
defined, 113
screening, 36
mind–body therapies, 686
mineralocorticoid antagonists (MRA), 151–152
Mini-Cog Assessment Instrument for Dementia, 36
Mini-Mental State Examination (MMSE), 115
Mini-Mental Status Examination (MMSE), 36
Mini-Nutritional Assessment Short Form (MNA-SF), 58
MIPS (Merit-Based Incentive Payment System), 739–740
mirabegron, 356–357
misuse. See abuse
mitral regurgitation
epidemiology, 158
management, 158
mitral stenosis
epidemiology, 157
management, 157–158
Modification of Diet in Renal Disease (MDRD), 46
MOLST (medical orders for life-sustaining treatments), 763
Montreal Cognitive Assessment (MoCA), 36, 115
mood disorders in the elderly
bipolar disorder, 249
chronic depression, 249
depression, 248–249
diagnostic tools for, 25
grief/bereavement, 249–250
prevalence of, 248
Morton’s neuroma, 562–563
motor neuron disease, 191
movement disorders in the elderly
gait disorders, 229–232
parkinsonism, 219
Parkinson’s disease (PD), 219–220
tremors, 218–220
Multidimensional Assessment of Older People in Primary Care (AMPI-AB), 28
multiple myeloma, 499–501
multiple sclerosis
epidemiology, 189–190
sensory disorders and, 194
treatment, 190
multiple system atrophy (MSA), 222
muscle weakness in the elderly evaluation, 191–192
Guillain-Barré syndrome, 190–191
motor neuron disease, 191
multiple sclerosis, 189–190
myasthenia gravis, 191
neurological causes of, 189–190
non-neurological causes of, 191
potential diagnostic red flags, 192
musculoskeletal injuries in the elderly and driving, 677
periprosthetic fractures, 442
musculoskeletal injuries in the elderly, injury factors
communion and bone weakness, 441–442
intraarticular fractures, 442
open fractures, 441
polytrauma, 441
musculoskeletal injuries in the elderly, management
ankle fractures, 448–449
distal radius fractures, 451–452
femoral neck fractures, 446
hip fractures, 444–446
intertrochanteric hip fractures, 446–448
preoperative considerations, 443–444
proximal humerus fractures, 449–451
vertebral compression fractures, 452
musculoskeletal injuries in the elderly, pathologic fractures
bisphosphonate use and, 443
metastatic disease, 442
musculoskeletal injuries in the elderly, patient factors
bone quality, 440–441
preinjury status, 440
soft-tissue quality, 441
systemic disease, 440
myasthenia gravis
epidemiology, 191
skeletal manifestations of, 191
treatment, 191
myelodysplastic syndrome, 497
myelopathy and gait, 228
myocardial infarction (MI)
acute ST-segment elevation myocardial infarction (STEMI) reperfusion, 145
clinical presentation, 140–141
complications, 146
diagnosis, 141–142
epidemiology, 139
non-ST-segment elevation reperfusion, 145
pharmacology management, 142–145
risk factors for, 139
naltrexone
for alcohol abuse, 264–265
for opioid abuse, 266
nasal cavity and sinus
age-related changes, 540
common pathologies, 540–541
National Standards for Culturally and Linguistically Appropriate Services (CLAS)
Civil Rights Act (1964), 710
communication and language assistance, 709
engagement, continuous improvement and accountability, 709
principal standard, 709
Naturally Occurring Retirement Communities (NORCs), 625
naturopathic medicine, 690–691
neurogenic bladder, 352–353
neurological problems.
See also cognitive impairment and driving, 677
headaches, 199–205
muscle weakness, 189–192

© in this web service Cambridge University Press & Assessment www.cambridge.org
Index

neurological problems (cont.)
seizure disorders, 195–197
sensory disorders, 192–196
NHANES audiometric battery
questionnaire, 23
nonarteritic ischemic optic neuropathy
(NAION), 533
nonselective beta-blockers, 72
nonsteroidal anti-inflammatory drugs
(NSAIDs) exercise guidelines, 72
non-syncopal falls, 92
nontuberculous mycobacterium (NTM),
274–275
normal pressure hydrocephalus (NPH)
and gait, 230–231
nurse-led CGA models, 28
nursing home. See also long-term care for
the elderly; skilled nursing facilities
and caregiver burden, 728
fecal incontinence, 370
health insurance coverage, 752
oral health in, 553
sleep disorders in, 241
urinary incontinence in, 359–360
nutraceuticals, 689
nutraceuticals and exercise performance,
67
nutrition and aging. See also malnutrition
in the elderly
for cancer, 688
cardiometabolic disease (CVD), 411
classification, 688–689
consequences, 54
demographics of, 54
dental caries, 549
frailty and, 86
for heart disease, 688
importance of, 54
natural foods and, 687
osteoporosis, 419
pressure injuries, 484–485, 488
requirements for, 58–60
nutrition and aging, diets
DASH diet, 687–688
fasting, 689
nutrition and aging, management
complementary and alternative
medicine (CAM) therapies, 687–689
guidelines for, 39
in long-term care, 61
tips for, 61
nutrition and aging, micronutrients
calcium, 60–61
importance of, 60
supplements, 61
vitamin B12, 60
vitamin D, 60
nutrition and aging, screening for
body mass index (BMI), 58
Malnutrition Screening Tool (MST), 58
Malnutrition Universal Screening Tool
(MUST), 58
Meals-on-Wheels mnemonic, 57
Mini-Nutritional Assessment Short
Form (MNA-SF), 58
obesity
exercise guidelines for, 67
frequency of, 24
sarcopenic, 56–57
obstructive sleep apnea (OSA). See sleep
apnea in the elderly
occupational therapists, 611
odynophagia, 288
Older Americans Act (OAA), 621
onychomycosis, 472, 560–561
opioid abuse, 257–258, 265–266
opioid analogs
and crash risk, 677
falls and, 48
oral cavity
age-related changes, 541
common pathologies, 542
oral health in the elderly
demographics, 24
dental caries, 548–549
importance of, 548
in long-term care, 553
palliative care, 553
primary care implications, 553–554
sarcopenia, 552–553
osteitis deformans, 537
osteitis fibrosa. See renal osteodystrophy
osteoarthritis
clinical presentation, 425
epidemiology, 425
foot, 426
hand, 425–426
knee, 426
spine/hip, 426
treatment, 426–427
osteopenia, 440–441
osteoporosis. See also bone conditions of
the elderly
aging and bone health, 418
exercise guidelines for, 67
Fracture Risk Assessment Tool
(FRAX), 35
screening, 35, 418–419
osteoporosis management
bone health nutrition, 419
nonpharmacological, 420
pharmacology, 420
serial bone density monitoring, 420
otolaryngal cancer
epidemiology, 550
etiology of, 550
incidence of, 550
risk factors, 550, 551
otolaryngology in the elderly
Bell’s palsy, 542
head and neck cancer, 543
nasal cavity and sinus, 540–541
oral health, 551–553
periodontal diseases, 549–550
otolaryngology in the elderly, ear
auditory, 538–539
balance, 539
cancers, 550–551
middle and inner ear, 537–538
oral cavity, 541–542
outer ear, 536–537
throat, 540
ototrauma deformans. See Paget’s disease
outbreak, defined, 771
outer ear otolaryngology
age-related changes, 536
common pathologies, 536–537
ovarian cancer
clinical evaluation, 378–379
epidemiology, 378
overflow urinary incontinence, 358
Paget’s disease, 422–423
palliative care
caregiving for, 730
diabetes mellitus management, 397
oral health in, 553
person-centered care (chronic kidney
disease), 332
practice transformation in elder care, 745
pandemic, defined, 771
pandemic effects on the elderly. See also
COVID-19
definitions, 771
Ebola virus disease (EVD), 774
H1N1 influenza virus, 773–774
HIV and, 772–773
impact of, 771
SARS and, 773
pandemic effects on the elderly, general
risks
comorbidities, 774–775
immunosenescence, 774
psychiatric disorders, 775–776
social determinants of health (SDOH), 775
pandemic effects on the elderly, response
to
communication, 777
diagnosis, 776
infection control, 775–776
preparedness for, 777
reporting mechanism, 776
response and recovery, 777
therapeutic modalities, 776–777

792
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>paraproteinemias</td>
</tr>
<tr>
<td>paraneoplastic cerebellar degeneration (PCD)</td>
</tr>
<tr>
<td>paraphimosis</td>
</tr>
<tr>
<td>Parkinsonian tremors</td>
</tr>
<tr>
<td>parkinsonism</td>
</tr>
<tr>
<td>clinical features of</td>
</tr>
<tr>
<td>defined</td>
</tr>
<tr>
<td>neuropsychiatric manifestations of</td>
</tr>
<tr>
<td>Parkinson’s disease (PD)</td>
</tr>
<tr>
<td>dementia and</td>
</tr>
<tr>
<td>differential diagnosis</td>
</tr>
<tr>
<td>epidemiology</td>
</tr>
<tr>
<td>etiology of</td>
</tr>
<tr>
<td>rehabilitation</td>
</tr>
<tr>
<td>Parkinson’s disease (PD) management</td>
</tr>
<tr>
<td>clinical algorithm</td>
</tr>
<tr>
<td>clinical treatment</td>
</tr>
<tr>
<td>deep brain stimulation (DBS)</td>
</tr>
<tr>
<td>pharmacology</td>
</tr>
<tr>
<td>psychosis and hallucinations</td>
</tr>
<tr>
<td>paronychia</td>
</tr>
<tr>
<td>participation, defined</td>
</tr>
<tr>
<td>pathogen, defined</td>
</tr>
<tr>
<td>patient autonomy in elderly health</td>
</tr>
<tr>
<td>family member involvement with patient consent</td>
</tr>
<tr>
<td>patient-assisted suicide</td>
</tr>
<tr>
<td>shared decision-making</td>
</tr>
<tr>
<td>Patient Health Questionnaire (PHQ-9)</td>
</tr>
<tr>
<td>patient knowledge in elderly health</td>
</tr>
<tr>
<td>steps of</td>
</tr>
<tr>
<td>understanding of family</td>
</tr>
<tr>
<td>Patient Protection and Affordable Care Act (2010)</td>
</tr>
<tr>
<td>patient-centered medical home (PCMH) model</td>
</tr>
<tr>
<td>pelvic organ prolapse</td>
</tr>
<tr>
<td>peptic ulcer disease (PUD)</td>
</tr>
<tr>
<td>defined</td>
</tr>
<tr>
<td>diagnosis</td>
</tr>
<tr>
<td>risk factors</td>
</tr>
<tr>
<td>treatment</td>
</tr>
<tr>
<td>percutaneous tibial nerve stimulation (PTNS)</td>
</tr>
<tr>
<td>Performance Oriented Mobility Assessment</td>
</tr>
<tr>
<td>pericardial constriction</td>
</tr>
<tr>
<td>pericardial effusion</td>
</tr>
<tr>
<td>pericarditis</td>
</tr>
<tr>
<td>periodontal diseases etiology of</td>
</tr>
<tr>
<td>gingivitis</td>
</tr>
<tr>
<td>periodontitis</td>
</tr>
<tr>
<td>prevalence of</td>
</tr>
<tr>
<td>prevention of</td>
</tr>
<tr>
<td>treatment</td>
</tr>
<tr>
<td>periodontitis</td>
</tr>
<tr>
<td>peripheral artery disease (PAD) in elderly adults classification</td>
</tr>
<tr>
<td>clinical presentation</td>
</tr>
<tr>
<td>defined</td>
</tr>
<tr>
<td>with diabetes</td>
</tr>
<tr>
<td>diagnosis</td>
</tr>
<tr>
<td>differential diagnosis</td>
</tr>
<tr>
<td>epidemiology</td>
</tr>
<tr>
<td>with hyperlipidemia</td>
</tr>
<tr>
<td>with hypertension</td>
</tr>
<tr>
<td>pathophysiology of</td>
</tr>
<tr>
<td>screening</td>
</tr>
<tr>
<td>secondary prevention trials</td>
</tr>
<tr>
<td>smoking</td>
</tr>
<tr>
<td>peripheral artery disease (PAD) in elderly adults management antithrombotic therapy</td>
</tr>
<tr>
<td>exercise</td>
</tr>
<tr>
<td>guidelines for</td>
</tr>
<tr>
<td>prognosis</td>
</tr>
<tr>
<td>surgery for</td>
</tr>
<tr>
<td>vasodilators</td>
</tr>
<tr>
<td>peripheral neuropathy and HIV</td>
</tr>
<tr>
<td>personality disorder in the elderly</td>
</tr>
<tr>
<td>clinical approaches to</td>
</tr>
<tr>
<td>defined</td>
</tr>
<tr>
<td>person-centered care (chronic kidney disease) advice directives</td>
</tr>
<tr>
<td>conservative management</td>
</tr>
<tr>
<td>geriatric assessment</td>
</tr>
<tr>
<td>guidelines for</td>
</tr>
<tr>
<td>importance of family caregivers in</td>
</tr>
<tr>
<td>palliative care</td>
</tr>
<tr>
<td>pes planus</td>
</tr>
<tr>
<td>Peyronie’s disease</td>
</tr>
<tr>
<td>pharmacodynamics in the elderly age-related changes</td>
</tr>
<tr>
<td>defined</td>
</tr>
<tr>
<td>pharmacokinetics in the elderly absorption</td>
</tr>
<tr>
<td>bioavailability</td>
</tr>
<tr>
<td>defined</td>
</tr>
<tr>
<td>distribution</td>
</tr>
<tr>
<td>metabolism</td>
</tr>
<tr>
<td>renal elimination</td>
</tr>
<tr>
<td>pharmacology. See also chemotherapy; polypharmacy problems in the elderly alcohol abuse</td>
</tr>
<tr>
<td>complementary and alternative medicine (CAM) therapies as substitute</td>
</tr>
<tr>
<td>and crash risk</td>
</tr>
<tr>
<td>for delirium</td>
</tr>
<tr>
<td>depression</td>
</tr>
<tr>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>drug interactions</td>
</tr>
<tr>
<td>essential tremors</td>
</tr>
<tr>
<td>exercise guidelines for</td>
</tr>
<tr>
<td>fecal incontinence</td>
</tr>
<tr>
<td>frailty and</td>
</tr>
<tr>
<td>gastroesophageal reflux disease (GERD)</td>
</tr>
<tr>
<td>geriatrics</td>
</tr>
<tr>
<td>glaucoma</td>
</tr>
<tr>
<td>and headaches</td>
</tr>
<tr>
<td>for insomnia</td>
</tr>
<tr>
<td>Medicare Part D</td>
</tr>
<tr>
<td>osteoporosis</td>
</tr>
<tr>
<td>Parkinson’s disease (PD)</td>
</tr>
<tr>
<td>pressure injuries</td>
</tr>
<tr>
<td>psychotropic effects from</td>
</tr>
<tr>
<td>and sexuality</td>
</tr>
<tr>
<td>start low and go slow maxim</td>
</tr>
<tr>
<td>stress urinary incontinence</td>
</tr>
<tr>
<td>urgency urinary incontinence</td>
</tr>
<tr>
<td>urinary catheters</td>
</tr>
<tr>
<td>phenotype model of frailty</td>
</tr>
<tr>
<td>pheochromocytoma</td>
</tr>
<tr>
<td>phimosis</td>
</tr>
<tr>
<td>phoca</td>
</tr>
<tr>
<td>photovaporization of the prostate (PVP)</td>
</tr>
<tr>
<td>Physical Activity Guidelines for Americans</td>
</tr>
<tr>
<td>physical activity in elderly adults after arthroplasty</td>
</tr>
<tr>
<td>benefits of</td>
</tr>
<tr>
<td>chronic disease</td>
</tr>
<tr>
<td>chronic disease and</td>
</tr>
<tr>
<td>consequences of not doing</td>
</tr>
<tr>
<td>COVID-19 and</td>
</tr>
<tr>
<td>demographics of</td>
</tr>
<tr>
<td>diabetes mellitus and</td>
</tr>
<tr>
<td>frailty and</td>
</tr>
<tr>
<td>guidelines for</td>
</tr>
<tr>
<td>injuries</td>
</tr>
<tr>
<td>intellectual disability (ID) and</td>
</tr>
<tr>
<td>medications and</td>
</tr>
<tr>
<td>social isolation and loneliness</td>
</tr>
<tr>
<td>physical activity in elderly adults, primary care role counseling approaches</td>
</tr>
<tr>
<td>exercise barriers</td>
</tr>
<tr>
<td>guidelines for</td>
</tr>
<tr>
<td>incentives for</td>
</tr>
<tr>
<td>physical therapy for pressure injuries</td>
</tr>
<tr>
<td>physician role in elderly health care advanced directives</td>
</tr>
<tr>
<td>advocate for patient</td>
</tr>
<tr>
<td>financials of</td>
</tr>
<tr>
<td>incorporate social determinants</td>
</tr>
<tr>
<td>leadership</td>
</tr>
</tbody>
</table>
physician role (cont.)
personal commitment, 1–2
person-centered primary care, 2
social support, 2
physician-assisted suicide, 5–6
Pilates, 687
plantar fasciitis, 563–564
pneumococcus, 38
pneumonia in the elderly
bacterial, 299–301
classification, 277
diagnosis, 277
prevalence of, 276–277
treatment, 277–278
POLST (physician orders for life-
sustaining treatment), 763
polycythemia vera (PV), 502
polymyalgia rheumatica (PMR)
clinical presentation, 430
epidemiology, 430
treatment, 430
polypharmacy problems in the elderly. See also
pharmacology
adverse drug reactions (ADRs), 47–49
Beers criteria, 46–47
deprescribing, 25, 50
drug adherence, 49–50
evaluation and assessment, 6–7
frequency of, 25, 44
in geropsychiatry, 253
gout, 429
medication strategies, 50
pharmacist partnering, 25
pharmacodynamic changes, 46
pharmacokinetic changes, 44–46
practice transformation in elder care, 745
STOPP/START criteria, 47
and surgery potential, 571–572
tremors and, 219–220
under-treatment, 49
positive airway pressure (PAP), 240
posterior tibial tendon dysfunction, 563
posterior vitreous detachment (PVD), 529
post-herpetic neuralgia, 193–194
post-traumatic stress disorder (PTSD), 614
practice transformation in elder care
care coordination, 746
culture of, 742–744
defined, 736
evolution of, 737–738
home-based care, 736
importance of, 736–737
role of subspecialty care, 738
triple aim, 737
practice transformation in elder care, best
takes, 745
practice transformation in elder care, payment models
Accurate Hierarchical Conditions Category (HCC), 739
Alternative Payment Models (APMs), 739
Cognitive Impairment Assessment and Care Planning, 738
Health Plan Employer Data and Information Set (HEDIS), 739
MACRA (Medicare Access and CHIP Reauthorization Act), 739–740
MIPS (Merit-Based Incentive Payment System), 739–740
Psychiatric Collaborative Care Model, 738
transformation components, 740–741
value-based care (VBC), 738
pramipexole, 223–224
Preclinical Screening and Resident Review (PASARR), 624
Preclinical models for aging interventions
reasons for, 15
relevance of, 15–16
types of, 16
pre-exposure prophylaxis (PrEP), 318–319
presbyopia, 528
pressure injuries
assessment, 485
classification, 478
diagnosis, 479–481
differential diagnosis, 481
epidemiology, 477
healing time, 477
pathophysiology of, 478–479
and quality of life, 477
risk assessment, 480
risk factors, 480–483
screening, 480
pressure injuries, management
epithelial advancement, 486
infection control, 486
moisture, 486
nutrition, 488
pharmacology, 487–488
tissue, 485–486
wound repair, 487
pressure injuries, prevention
incontinence management, 485
mobility equipment, 484
nutrition, 484
pressure redistribution support
surfaces, 484
prophylactic dressings, 484
scheduled repositioning, 483
preventive health, common geriatric issues
dementia, 36
depression, 36
driving safely, 37
elder abuse, 37
falls, 36
hearing impairment, 37
visual impairment, 37
preventive health for the elderly
goals for, 33
Medicare Annual Wellness Visit (AWV), 33
nutrition and exercise, 7
recommendations for, 7
preventive health, immunizations
hepatitis A and B, 38–39
herpes zoster, 38
influenza, 37–38
pneumococcus, 38
tetanus, 38
preventive health, lifestyle
alcohol abuse, 39
nutrition, 39
physical activity, 39
sexually transmitted infections (STIs), 39–40
smoking, 39
preventive health screening for the elderly
abdominal aortic aneurysm screening, 35
cancer, 33–34
hepatitis B, 35
hepatitis C, 35–36
hyperlipidemia, 35
hypertension, 34–35
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>hypothyroidism, 35</td>
</tr>
<tr>
<td>osteoporosis, 35</td>
</tr>
<tr>
<td>type 2 diabetes, 35</td>
</tr>
<tr>
<td>primary aldosteronism (PA), 390–391</td>
</tr>
<tr>
<td>Primary Care Assessment Tool for Elderly (PASTEL), 28</td>
</tr>
<tr>
<td>primary care physician-led CGA models, 27–28</td>
</tr>
<tr>
<td>primary headaches cluster headaches, 199</td>
</tr>
<tr>
<td>defined, 199</td>
</tr>
<tr>
<td>migraines, 199</td>
</tr>
<tr>
<td>prophylactic treatment, 201</td>
</tr>
<tr>
<td>tension, 199–201</td>
</tr>
<tr>
<td>treatment, 201</td>
</tr>
<tr>
<td>types of, 200</td>
</tr>
<tr>
<td>primary hyperparathyroidism (PHPT) bone condition of the elderly, 422</td>
</tr>
<tr>
<td>epidemiology, 383</td>
</tr>
<tr>
<td>evaluation, 383</td>
</tr>
<tr>
<td>medical management of, 384</td>
</tr>
<tr>
<td>surgery for, 383–384</td>
</tr>
<tr>
<td>primary myelofibrosis (PMF), 502</td>
</tr>
<tr>
<td>primary open-angle glaucoma (POAG), 529</td>
</tr>
<tr>
<td>primary progressive aphasia (PPA), 117</td>
</tr>
<tr>
<td>principle of double effect, 764–765</td>
</tr>
<tr>
<td>Program of All-Inclusive Care for the Elderly (PACE), 3</td>
</tr>
<tr>
<td>progressive supranuclear palsy (PSP), 222</td>
</tr>
<tr>
<td>prostate cancer clinical presentation, 511</td>
</tr>
<tr>
<td>epidemiology, 511</td>
</tr>
<tr>
<td>prognosis, 512</td>
</tr>
<tr>
<td>screening, 34, 511</td>
</tr>
<tr>
<td>staging, 512</td>
</tr>
<tr>
<td>prostate cancer management active surveillance, 512</td>
</tr>
<tr>
<td>advanced cancer, 513</td>
</tr>
<tr>
<td>brachytherapy, 513</td>
</tr>
<tr>
<td>castrate-resistant prostate cancer (CRPC), 513</td>
</tr>
<tr>
<td>localized disease, 512</td>
</tr>
<tr>
<td>radiation therapy, 513</td>
</tr>
<tr>
<td>radical prostatectomy (RP), 512</td>
</tr>
<tr>
<td>watchful waiting, 512</td>
</tr>
<tr>
<td>prostatitis clinical presentation, 343</td>
</tr>
<tr>
<td>epidemiology, 343</td>
</tr>
<tr>
<td>management, 343</td>
</tr>
<tr>
<td>and prostatodynia, 343</td>
</tr>
<tr>
<td>prostatodynia, 343</td>
</tr>
<tr>
<td>proton pump inhibitors (PPIs), 72</td>
</tr>
<tr>
<td>provider cultural competence, 710–712</td>
</tr>
<tr>
<td>proximal humerus fractures, 449–451</td>
</tr>
<tr>
<td>pruritis, 374, 466–467, 558</td>
</tr>
<tr>
<td>psoriasis, 465</td>
</tr>
<tr>
<td>Psychiatric Collaborative Care Model, 738</td>
</tr>
<tr>
<td>psychiatric disorders and driving, 677</td>
</tr>
<tr>
<td>and HIV, 315–316</td>
</tr>
<tr>
<td>pandemic effects on, 775–776</td>
</tr>
<tr>
<td>psychosis in the elderly delusional disorder, 251</td>
</tr>
<tr>
<td>hallucinations, 251</td>
</tr>
<tr>
<td>from medications, 251</td>
</tr>
<tr>
<td>schizophrenia, 251</td>
</tr>
<tr>
<td>treatment, 251</td>
</tr>
<tr>
<td>psychotherapy for the elderly family assessment, 253–254</td>
</tr>
<tr>
<td>individual, 253</td>
</tr>
<tr>
<td>marital, 253</td>
</tr>
<tr>
<td>obsessions, 524–525</td>
</tr>
<tr>
<td>pulmonary embolism (PE) diagnosis, 278</td>
</tr>
<tr>
<td>epidemiology, 278</td>
</tr>
<tr>
<td>special considerations, 279</td>
</tr>
<tr>
<td>treatment, 278</td>
</tr>
<tr>
<td>pulmonary issues in the elderly and driving, 677</td>
</tr>
<tr>
<td>exercise guidelines for, 71</td>
</tr>
<tr>
<td>intensive care, 279–280</td>
</tr>
<tr>
<td>natural aging process, 270</td>
</tr>
<tr>
<td>prevalence of, 270</td>
</tr>
<tr>
<td>pulmonary issues in the elderly, acute conditions pneumonia, 276–278</td>
</tr>
<tr>
<td>pulmonary embolism (PE), 278–279</td>
</tr>
<tr>
<td>pulmonary issues in the elderly, chronic lung disease bronchiectasis, 274</td>
</tr>
<tr>
<td>chronic obstructive pulmonary disease (COPD), 270–274</td>
</tr>
<tr>
<td>interstitial lung disease (ILD), 275–276</td>
</tr>
<tr>
<td>obstructive sleep apnea (OSA), 276</td>
</tr>
<tr>
<td>qi gong, 687</td>
</tr>
<tr>
<td>quinolones, 72</td>
</tr>
<tr>
<td>radical prostatectomy (RP), 512</td>
</tr>
<tr>
<td>Rapid Geriatric Assessment (RGA), 28</td>
</tr>
<tr>
<td>rasagiline, 223</td>
</tr>
<tr>
<td>REACH intervention trial (Resources for Enhancing Alzheimer’s Caregiver Health), 730–731</td>
</tr>
<tr>
<td>rehabilitation, 572</td>
</tr>
<tr>
<td>activity, 580</td>
</tr>
<tr>
<td>functional aging and, 578–579</td>
</tr>
<tr>
<td>functional assessment (CGA), 579–581</td>
</tr>
<tr>
<td>impairment, 580</td>
</tr>
<tr>
<td>importance of, 578</td>
</tr>
<tr>
<td>participation, 580</td>
</tr>
<tr>
<td>professional team, 582</td>
</tr>
<tr>
<td>rehabilitation, common problems hip fractures, 588–589</td>
</tr>
<tr>
<td>lower-extremity amputation, 589</td>
</tr>
<tr>
<td>Parkinson’s disease (PD), 588</td>
</tr>
<tr>
<td>stroke, 586–588</td>
</tr>
<tr>
<td>rehabilitation assistive devices canes, 583–584</td>
</tr>
<tr>
<td>crutches, 584</td>
</tr>
<tr>
<td>mechanical aids, 586</td>
</tr>
<tr>
<td>reasons for, 583</td>
</tr>
<tr>
<td>walkers, 584</td>
</tr>
<tr>
<td>wheelchairs, 584–586</td>
</tr>
<tr>
<td>rehabilitation settings home, 583</td>
</tr>
<tr>
<td>inpatient facilities, 582–583</td>
</tr>
<tr>
<td>multidisciplinary versus interdisciplinary, 582</td>
</tr>
<tr>
<td>selection, 583</td>
</tr>
<tr>
<td>solitude, 583</td>
</tr>
<tr>
<td>Reiki, 687</td>
</tr>
<tr>
<td>remitting seronegative symmetric synovitis with pitting edema (RS3PE), 431</td>
</tr>
<tr>
<td>renal disease and HIV, 315</td>
</tr>
<tr>
<td>renal elimination pharmacology, 45–46</td>
</tr>
<tr>
<td>renal osteodystrophy, 423</td>
</tr>
<tr>
<td>resilience and frailty, 87</td>
</tr>
<tr>
<td>resource-based relative value system (RBRVS), 757</td>
</tr>
<tr>
<td>respect and value of patient in elderly health breakdown of stereotypes, 8–9</td>
</tr>
<tr>
<td>cultural connection, 8</td>
</tr>
<tr>
<td>worker demographics, 9</td>
</tr>
<tr>
<td>rest tremors, 218, 220–221</td>
</tr>
<tr>
<td>retinal artery occlusions (RAO), 531</td>
</tr>
<tr>
<td>retinal detachment, 530</td>
</tr>
<tr>
<td>retinal vein occlusions (RVO), 531</td>
</tr>
<tr>
<td>retinopathy, diabetic, 530–531</td>
</tr>
<tr>
<td>retirement Age Discrimination in Employment Act of 1967, 700</td>
</tr>
<tr>
<td>defined, 699</td>
</tr>
<tr>
<td>demographics of, 699–700</td>
</tr>
<tr>
<td>perspectives on, 699</td>
</tr>
<tr>
<td>transitional nature of, 700</td>
</tr>
<tr>
<td>transitional types, 700</td>
</tr>
<tr>
<td>retirement contextual factors caregiving burden, 702–703</td>
</tr>
<tr>
<td>chronic health conditions, 701</td>
</tr>
<tr>
<td>emotional health and social well-being after, 701–702</td>
</tr>
<tr>
<td>psychological well-being after, 701</td>
</tr>
<tr>
<td>remote work, 703</td>
</tr>
<tr>
<td>social networks and, 703</td>
</tr>
<tr>
<td>social reference groups, 702</td>
</tr>
<tr>
<td>sociodemographic, 702</td>
</tr>
<tr>
<td>reversible dementia, 115</td>
</tr>
<tr>
<td>rheumatoid arthritis (RA) clinical presentation, 427</td>
</tr>
<tr>
<td>epidemiology, 427</td>
</tr>
</tbody>
</table>
Index

rheumatoid arthritis (RA) (cont.)
treatment, 427–428
rheumatologic disease in the elderly,
425–427
rhinitis, ... 26, 745
and intellectual disabilities, 606
pandemic effects on, 775
public health data and, 742
Index
796

Edited by Jan Busby-Whitehead, Samuel C. Durso, Christine Arenson, Mary H. Palmer, Rebecca Elon, William Reichel

796

© in this web service Cambridge University Press & Assessment

www.cambridge.org
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trails-Making B test, 679</td>
</tr>
<tr>
<td>transcatheter aortic valve replacement (TAVR), 156–157</td>
</tr>
<tr>
<td>transdermal patch (urinary incontinence), 356</td>
</tr>
<tr>
<td>transient ischemic attack (TIA) ABCD 2 criteria for, 209 risk factors, 210 risk stratification, 209</td>
</tr>
<tr>
<td>translational aging research chronic disease trajectory, 12–13 compression of morbidity and, 13 economic reasons for, 12 frailty and, 13 geroscience approach, 13 societal benefits, 13–14 transurethral microwave thermotherapy (TMT), 342</td>
</tr>
<tr>
<td>tremors defined, 218 polypharmacy problems, 219–220 tremors, types of action tremors, 218 essential tremors, 218–220 essential versus Parkinsonian, 218 intention tremors, 219 Parkinsonian tremors, 218 rest tremors, 218 Triage-Titrate-Test method (dizziness), 103</td>
</tr>
<tr>
<td>tricuspid regurgitation, 158 tricyclic antidepressants (TCAs), 47 trifluropiridine, 223 trosquip, 356 tuberculosis (TB) clinical presentation, 301–302 epidemiology, 301 screening, 302 treatment, 302</td>
</tr>
</tbody>
</table>
posterior vitreous detachment (PVD), 529
presbyopia, 528
retinal artery occlusions (RAO), 531
retinal detachment, 530
retinal vein occlusions (RVO), 531
visual impairment, conjunctivitis
allergic, 527
bacterial, 526
chronic, 527
physiology of, 526
viral, 526–527
visual impairment, corneal abrasions, 527
physiology of, 527
visual impairment, eyelid neoplasms
basal cell carcinoma, 525
epidemiology, 525
sebaceous cell carcinoma, 525
squamous cell carcinoma, 525
visual impairment, eyelids
age-related structural changes to, 524
dermatochalasis, 525
ectropion, 524
entropion, 524
epiphora, 525
floppy eyelid syndrome, 525
lacrimal system, 524
ptosis, 524–525
visual impairment, optic nerve disorders
giant cell arteritis (GCA), 532–533
nonarteritic ischemic optic neuropathy (NAION), 533
vitamin B12, 60, 194, 497
vitamin D, 60
vitamin D deficiency epidemiology, 384
treatment benefits, 384
voice
age-related changes, 540
common pathologies, 540
Vulnerable Elder Protection Team (VEPT), 670
vulvar cancer, 379
vulvodynia, 374
vulvovaginitis, 373
waddling gait, 232
walkers, 584
warfarin and atrial fibrillation (AF), 161
for stroke prevention, 211
wheelchairs, 584–586
Whisper Test, 23
xerosis, 558
yoga, 687
Zenker’s diverticulum, 540